Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, announced today that it has opened a new
50,000-square-foot facility in Wuxi, China. This strategic move
increases the company's manufacturing capacity to meet the growing
worldwide demand for comprehensive cell analysis solutions.
The Wuxi facility offers the advantage of
fostering unique vendor relationships and further facilitates Cytek
to manufacture its own components, distinguishing the company from
other industry players. In addition to bolstering Cytek's
manufacturing capabilities, the facility also accommodates Cytek
Wuxi operations, research and development, marketing, human
resources, and sales teams.
Recognized as a pioneer in spectral flow
cytometry, Cytek is the creator of the first commercialized
fluorescence-based flow cytometry platform to achieve 40 colors –
effectively shifting the paradigm of what scientists thought was
possible in flow cytometry. Cytek’s portfolio of comprehensive
solutions empower scientists, allowing them to go even further with
their research – all with greater ease and shorter time to
insights.
Cytek’s products portfolio include the Cytek
Aurora™ and Cytek Northern Lights™ cell analyzers, Cytek Aurora™ CS
cell sorter, Amnis® and Guava® instruments, Cytek Orion™ reagent
cocktail preparation system, reagents, software, and services. The
Cytek Aurora CS system, in particular, is the only cell sorter on
the market that offers the unique ability to combine the advantages
of Full Spectrum Profiling™ (FSP™) technology with high-performance
cell sorting. Since the Cytek Aurora CS system and the Cytek Aurora
cell analyzer share the same FSP technology, assays can be easily
transferred from one to the other without redesigning panels,
reconfiguring detector systems, or sacrificing resolution. The
Cytek Aurora CS and Cytek Aurora systems are the first and only
paired spectral cell sorter-analyzer combo in the industry.
“The increasing application of cellular analysis
in various fields, including immuno-oncology, infectious diseases
and immunology, has led to a rising need for advanced cell analysis
solutions – and we are taking a proactive approach to accommodate
it,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “Our
roadmap has us continuing to expand our global footprint – and
continuing to give scientists the tools and support they need to
advance their research.”
Please visit www.cytekbio.com for more
information.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; Cytek Orion™ reagent cocktail
preparation system, and reagents, software and services to provide
a comprehensive and integrated suite of solutions for its
customers. Cytek is headquartered in Fremont, California with
offices and distribution channels across the globe. More
information about the company and its products is available at
www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek
Aurora, Northern Lights, Cytek Orion, Amnis and Guava are
trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s business plans and market
opportunities; Cytek’s ability to meet the growing worldwide demand
for comprehensive cell analysis solutions; and Cytek’s plans to
continue expanding its global footprint. These statements are based
on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management.
These statements also deal with future events and involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as those
relating to Cytek’s ability to manage the growth and complexity of
its organization; Cytek’s ability to manage relationships with key
customers and suppliers; Cytek’s ability to retain key employees;
Cytek’s ability to continue to stay in compliance with its material
contractual obligations, applicable laws and regulations; global
economic and market conditions; competition; and Cytek’s dependence
on certain sole and single source suppliers. You should refer to
the section entitled “Risk Factors” set forth in Cytek’s most
recent Quarterly Report on Form 10-Q filed with the SEC and other
filings Cytek Biosciences makes with the SEC from time to time for
a discussion of important factors that may cause actual results to
differ materially from those expressed or implied by Cytek’s
forward-looking statements. Although Cytek believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/85b3021a-0730-4ed8-8f8a-2f48a4ba5662https://www.globenewswire.com/NewsRoom/AttachmentNg/7dfb4b66-ea4c-47bd-a1ab-8343ad30bb60
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From May 2024 to Jun 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Jun 2023 to Jun 2024